GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (NAS:CAPR) » Definitions » Shiller PE Ratio

Capricor Therapeutics (Capricor Therapeutics) Shiller PE Ratio : (As of Jun. 10, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Capricor Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Capricor Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Capricor Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics Shiller PE Ratio Chart

Capricor Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Capricor Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Capricor Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Capricor Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Capricor Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's Shiller PE Ratio falls into.



Capricor Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Capricor Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Capricor Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.31/131.7762*131.7762
=-0.310

Current CPI (Mar. 2024) = 131.7762.

Capricor Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -1.300 100.560 -1.704
201409 -1.300 100.428 -1.706
201412 -1.600 99.070 -2.128
201503 -2.300 99.621 -3.042
201506 -1.900 100.684 -2.487
201509 -1.800 100.392 -2.363
201512 -2.100 99.792 -2.773
201603 -2.600 100.470 -3.410
201606 -2.600 101.688 -3.369
201609 -2.900 101.861 -3.752
201612 -2.100 101.863 -2.717
201703 -1.700 102.862 -2.178
201706 -1.600 103.349 -2.040
201709 -1.200 104.136 -1.519
201712 4.200 104.011 5.321
201803 -1.400 105.290 -1.752
201806 -1.420 106.317 -1.760
201809 -1.350 106.507 -1.670
201812 -1.100 105.998 -1.368
201903 -0.750 107.251 -0.922
201906 -0.590 108.070 -0.719
201909 -0.430 108.329 -0.523
201912 -0.340 108.420 -0.413
202003 -0.300 108.902 -0.363
202006 -0.230 108.767 -0.279
202009 -0.200 109.815 -0.240
202012 -0.210 109.897 -0.252
202103 -0.230 111.754 -0.271
202106 -0.210 114.631 -0.241
202109 -0.170 115.734 -0.194
202112 -0.260 117.630 -0.291
202203 -0.320 121.301 -0.348
202206 -0.290 125.017 -0.306
202209 -0.260 125.227 -0.274
202212 -0.310 125.222 -0.326
202303 -0.310 127.348 -0.321
202306 -0.290 128.729 -0.297
202309 -0.250 129.860 -0.254
202312 0.020 129.419 0.020
202403 -0.310 131.776 -0.310

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Capricor Therapeutics  (NAS:CAPR) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Capricor Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Capricor Therapeutics (Capricor Therapeutics) Business Description

Traded in Other Exchanges
Address
10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
Executives
David B Musket director C/O CONOR MEDSYSTEMS, INC., 1003 HAMILTON COURT, MENLO PARK CA 94025
Collier Earl M Jr director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Paul Gisbert Auwaerter director C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Mike Kelliher director C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Philip J Gotwals director C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Xavier Avat officer: CHIEF BUSINESS OFFICER 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Karimah Es Sabar director C/O 8840 WILSHIRE BOULEVARD, 2ND FLOOR, BEVERLY HILLS CA 90211
Linda Marban director, officer: CHIEF EXECUTIVE OFFICER C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Dunbar George W Jr director C/O COMPETITIVE TECHNOLOGIES, INC., 777 COMMERCE DRIVE, SUITE 100, FAIRFIELD CT 06825
Karen Krasney officer: EVP, GENERAL COUNSEL C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Anthony Bergmann officer: CHIEF FINANCIAL OFFICER C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Louis Manzo director C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Cedars Sinai Medical Center 10 percent owner 8700 BEVERLY BLVD, LOS ANGELES CA 90048-1865
St. John Edward A. 10 percent owner 2560 LORD BALTIMORE DRIVE, BALTIMORE MD 21244
Leland Gershell officer: Chief Financial Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., STE 306, NEW YORK NY 10022

Capricor Therapeutics (Capricor Therapeutics) Headlines

From GuruFocus